Ticlopidine use after coronary stenting can rarely cause severe agranulocytosis, highlighting the need for regular blood count monitoring during therapy.
Answers are grounded in this paper and cite their sources.
Supports hematologic monitoring with ticlopidine; leaves open systematic risk assessment in post-stent patients.
Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease. It is rarely associated with severe bone marrow suppression. A case of an elderly woman is reported who developed febrile agranulocytosis two months after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with granulocyte colony-stimulating factor (G-CSF). All patients should have regular monitoring of their blood counts during therapy with ticlopidine.
No takes yet. Share an insight, caveat, or question.
Sarı et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: